New York State Common Retirement Fund Purchases 31,692 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

New York State Common Retirement Fund increased its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 137.2% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 54,792 shares of the company’s stock after buying an additional 31,692 shares during the quarter. New York State Common Retirement Fund’s holdings in Sana Biotechnology were worth $1,234,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in SANA. State Street Corp lifted its stake in Sana Biotechnology by 836.0% in the 2nd quarter. State Street Corp now owns 1,976,442 shares of the company’s stock worth $38,857,000 after purchasing an additional 1,765,281 shares in the last quarter. Regents of The University of California purchased a new stake in Sana Biotechnology in the 3rd quarter worth $8,727,000. Public Sector Pension Investment Board lifted its stake in Sana Biotechnology by 9.1% in the 2nd quarter. Public Sector Pension Investment Board now owns 4,508,111 shares of the company’s stock worth $88,629,000 after purchasing an additional 376,862 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp lifted its stake in Sana Biotechnology by 337.5% in the 2nd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 279,160 shares of the company’s stock worth $5,488,000 after purchasing an additional 215,350 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Sana Biotechnology by 134.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 367,988 shares of the company’s stock worth $7,235,000 after purchasing an additional 211,202 shares in the last quarter. Institutional investors and hedge funds own 56.81% of the company’s stock.

Shares of SANA stock opened at $11.37 on Friday. The stock has a market cap of $2.15 billion and a P/E ratio of -1.22. Sana Biotechnology, Inc. has a 52 week low of $10.78 and a 52 week high of $44.60. The company’s fifty day simple moving average is $17.17 and its two-hundred day simple moving average is $19.58.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Sunday, November 7th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.03.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.

Further Reading: Asset Allocation, Balancing Your Investments

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA).

Institutional Ownership by Quarter for Sana Biotechnology (NASDAQ:SANA)

Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.